Samarth Kulkarni
2017
In 2017, Samarth Kulkarni earned a total compensation of $6.9M as Chief Executive Officer at CRISPR Therapeutics AG, a 429% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $196,264 |
|---|---|
| Option Awards | $5,816,201 |
| Salary | $404,650 |
| Stock Awards | $506,406 |
| Other | $10,744 |
| Total | $6,934,265 |
Kulkarni received $5.8M in option awards, accounting for 84% of the total pay in 2017.
Kulkarni also received $196.3K in non-equity incentive plan, $404.7K in salary, $506.4K in stock awards and $10.7K in other compensation.
Rankings
In 2017, Samarth Kulkarni's compensation ranked 1,183rd out of 14,666 executives tracked by ExecPay. In other words, Kulkarni earned more than 91.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,183 out of 14,666 | 92nd |
Division Manufacturing | 397 out of 5,768 | 93rd |
Major group Chemicals And Allied Products | 105 out of 2,074 | 95th |
Industry group Drugs | 72 out of 1,730 | 96th |
Industry Biological Products, Except Diagnostic Substances | 13 out of 316 | 96th |
Source: SEC filing on April 30, 2019.
Kulkarni's colleagues
We found four more compensation records of executives who worked with Samarth Kulkarni at CRISPR Therapeutics AG in 2017.
News
CRISPR Therapeutics AG CEO Samarth Kulkarni's 2021 pay jumps 87% to $17M
April 25, 2022
CRISPR Therapeutics AG CEO Samarth Kulkarni's 2020 pay falls 44% to $9.1M
April 28, 2021
CRISPR Therapeutics AG CEO Samarth Kulkarni's 2019 pay jumps 67% to $16M
April 24, 2020
CRISPR Therapeutics AG CEO Samarth Kulkarni's 2018 pay jumps 40% to $9.7M
April 30, 2019